Biomerica’s Stock Soars with New FDA Clearance Biomerica’s Stock Soars with New FDA Clearance

Actionable Trade Ideas

always free


Biomerica IncΒ BMRA has received FDA 510(k) clearance for its Hp Detect Stool Antigen ELISA test, designed to detect the presence of theΒ H. pylori bacteria.

H. pylori infection affects half the world’s population.

The Biomerica Hp Detect test finds the H. pylori bacteria, which infects approximately 35% of the U.S. population.

Over 80% of gastric cancers are caused by H. pylori infection, and gastric cancer is the third most common cause of cancer-related death worldwide.

Physicians and medical centers can use the results from the Hp Detect Stool Antigen test to diagnose the presence of H. pylori and assess H. pylori infection status after treatment.

Biomerica’s Chief Executive Officer Zack Irani stated, β€œThis FDA clearance is a milestone in our commitment to bring a diagnostic solution for over 115 million people suffering from H. pylori infection across the U.S.”

Price Action:Β BMRA shares are up 57.58% at $1.56 during the premarket session on the last check Monday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.